Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FAST alone Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

NCT03613649
View directory record Official record
Conditions
Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions
AZD0914, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Treatment Resistant Geriatric Depression in Primary Care

NCT01392287
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

NCT00802074
View directory record Official record
Conditions
Healthy
Interventions
Raltegravir, Fosamprenavir, Ritonavir
Drug
Lead sponsor
Garden State Infectious Disease Associates, PA
Other
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Mirtoselect®, Virtiva®, and Enovita® on Cognitive Performance and Mood States

NCT06309914
View directory record Official record
Conditions
Mental Processes, Cognitive Change, Mood Change
Interventions
Placebo, Enovita Grape Seed Extract, Mirtoselect Bilberry Extract, Virtiva Plus Ginko Biloba Extract
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
25 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 23, 2026, 8:40 PM EDT
Withdrawn No phase listed Observational

T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events

NCT01796743
View directory record Official record
Conditions
Myocardial Infarction, Acute
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

NCT02045849
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

NCT05431153
View directory record Official record
Conditions
Healthy
Interventions
Single dose of PF-07104091 as Tablet Formulation A (Treatment A), Single dose of PF-07104091 as Tablet Formulation B (Treatment B), Single dose of PF-07104091 as Tablet Formulation C (Treatment C), Single dose of PF-07104091 as Tablet Formulation D (Treatment D), Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation

NCT01080612
View directory record Official record
Conditions
Healthy
Interventions
330 mg pregabalin controlled release, 300 mg pregabalin immediate release
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

NCT01161966
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide, Zonegran
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2010 · Synced Oct 23, 2026, 8:40 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Transit Time and Bacterial Overgrowth Using SmartPill Capsule

NCT00577772
View directory record Official record
Conditions
Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
Interventions
Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
Drug · Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects

NCT00608959
View directory record Official record
Conditions
Infection
Interventions
omiganan 1% gel, chlorhexidine 2% solution
Drug
Lead sponsor
Cadence Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy Adults

NCT06466473
View directory record Official record
Conditions
Healthy
Interventions
Phenytoin (Ascoli), Phenytoin (Vega Baja)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 23, 2026, 8:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pain Perception: Lidocaine Rate/Temp/Buffer

NCT02823002
View directory record Official record
Conditions
Pain
Interventions
Slow, Room Temperature Injection, Rapid, Room Temperature Injection, Slow, Warm Temperature Injection, Rapid, Warm Temperature Injection, Buffered Injection, Non-Buffered Injection, Lidocaine, Buffer
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 23, 2026, 8:40 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of Lycopene and Isoflavones on Glucose Metabolism

NCT01377961
View directory record Official record
Conditions
Metabolic Syndrome, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks, Screening, OGTT, Anthropometrics and Blood pressure, Blood Drawing
Drug · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

NCT03061981
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Metformin, DA-1241
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice

NCT00984009
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Grapefruit Juice
Drug · Other
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

NCT01068717
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Results available

Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study

NCT04499950
View directory record Official record
Conditions
Breast Cancer, Overweight or Obesity
Interventions
Contrave, Behavioral Weight Loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Benazepril HCl 40 mg Tablets, Fasting

NCT00836576
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Not applicable Interventional Results available

A Multi-Center Study of Reading Rehabilitation in Macular Disease

NCT00746668
View directory record Official record
Conditions
Age Related Maculopathy, Retinal Degeneration
Interventions
Module 1: Visual Awareness and Eccentric Viewing, Module 2: Control of Reading Eye Movements, Module 3: Reading Practice with RSVP
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy Subjects

NCT05318040
View directory record Official record
Conditions
Alzheimer Disease
Interventions
CMS121, Placebo
Drug
Lead sponsor
Virogenics, Inc.
Industry
Eligibility
19 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes

NCT00312130
View directory record Official record
Conditions
Pre-diabetes
Interventions
Vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 23, 2026, 8:40 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

NCT05094336
View directory record Official record
Conditions
Advanced MTAP-null Solid Tumors
Interventions
Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 8:40 PM EDT
Completed Not applicable Interventional Results available

A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting

NCT00440232
View directory record Official record
Conditions
Migraine
Interventions
Frovatriptan, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 23, 2026, 8:40 PM EDT